ABVC BioPharma, Inc. (ABVC) |
|
1 0.043 (4.5%)
|
09-27 16:00 |
|
Open: |
0.95 |
Pre. Close: |
0.9569 |
|
High:
|
1.03 |
Low:
|
0.94 |
|
Volume:
|
35,873 |
Market Cap:
|
4(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 4:17:26 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
  |
| Target: |
Six months: 1.84 One year: 2.39 |
| Support: |
Support1: 0.81 Support2: 0.68 |
| Resistance: |
Resistance1: 1.58 Resistance2: 2.04 |
| Pivot: |
1.04  |
| Moving Average: |
MA(5): 0.95 MA(20): 1.08
MA(100): 4.09 MA(250): 5.95 |
| MACD: |
MACD(12,26): -0.4 Signal(9): -0.4 |
| Stochastic oscillator: |
%K(14,3): 26.9 %D(3): 21.5 |
| RSI: |
RSI(14): 33.2 |
| 52-week: |
High: 18.7 Low: 0.81 |
| Average Vol(K): |
3-Month: 872 (K) 10-Days: 77 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ABVC ] has closed above bottom band by 36.0%. Bollinger Bands are 82.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.97 - 0.98 |
0.98 - 0.98 |
|
Low:
|
0.87 - 0.87 |
0.87 - 0.88 |
|
Close:
|
0.95 - 0.96 |
0.96 - 0.96 |
|
Company Description |
|
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation. |
Headline News |
Mon, 18 Sep 2023
Is ABVC Biopharma Inc (ABVC) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
Wed, 23 Aug 2023
ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study - Yahoo Finance
Sun, 13 Aug 2023
ABVC BioPharma announces approved plan for pilot Good ... - Modern Retina
Thu, 10 Aug 2023
ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement - Yahoo Finance
Mon, 31 Jul 2023
ABVC BioPharma Announces Closing on $1.75 Million Registered ... - GlobeNewswire
Mon, 24 Jul 2023
ABVC BioPharma Announces Reverse Stock Split - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
4 (M) |
|
% Held by Insiders
|
2.68e+006 (%) |
|
% Held by Institutions
|
38.9 (%) |
|
Shares Short
|
176 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.092e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
430 |
|
Return on Equity (ttm)
|
-59.3 |
|
Qtrly Rev. Growth
|
765640 |
|
Gross Profit (p.s.)
|
-316.13 |
|
Sales Per Share
|
-914.3 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
-3.6 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-3 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
-2.59 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
19820 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
